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Antibody directed against a tumor was shown to cause the suppression of the 
growth of that  tumor by Gorer  (1). Many studies have been carried out to 
delineate the active classes of antibody and the effectors that participate in this 
reaction (2-12). In the series of experiments presented in this paper, we have 
quantitatively analyzed some of the factors which may influence the effective- 
ness  of antibody  in  tumor suppression.  The  development of a  macrophage 
shortage with increasing tumor size emerged as an important factor that can 
limit the effectiveness of the antibody. 
Materials and Methods 
Mice.  Mice of the inbred strain C3H/HeN MTV- (C3H) ~  of either sex, aged 8-12 wk were used 
throughout the experiments. They were obtained from the National Cancer Institute through the 
courtesy of the Frederick Cancer Research Center, Frederick, Md. 
Tumor.  The C3H lymphoma 6C3HED,  obtained from the Jackson Laboratory, Bar Harbor, 
Maine, was maintained by inoculating 4 ×  10  ~ tumor cells into the calf muscle of syngeneic C3H 
mice. The term syngeneic is used only to indicate that the tumor originated in a  C3H mouse. 
Tumor  was harvested  12-14  days  after  inoculation and  minced in  RPMI  1640 tissue  culture 
medium (Microbiological Associates, Bethesda, Md.)  containing 0.1%  C3H  mouse serum  (me- 
dium).  The minced tumor was pressed through a  stainless steel screen. The cells were washed 
three times in the same medium by centrifugation. After the last wash, the cells were suspended 
and 3  min was allowed for clumps to settle in the centrifuge tube.  The top two-thirds of the 
supernate were collected and the cell count was adjusted to the desired numbers. All procedures 
were carried out under aseptic conditions with sterile instruments. 
Preparation  of Antibody.  Antibody against the  tumor  was  raised in  syngeneic C3H  mice 
according to the method of Pasternack et al. 2 Briefly, C3H mice were inoculated weekly with 2 × 
107  tumor  cells  of a  tissue  culture  line  in  50%  saline-complete Freund's  adjuvant  emulsion 
mtraperitoneally. After 4-5 wk, immune ascites developed and the animals were tapped with a 16- 
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grant from the Leukemia Research Foundation, Inc. This investigation was carried out while 
Hyun S. Shin was a recipient of a National Institute of Health Career Development Award GM- 
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Abbreviations  used in this paper:  C3H, C3H/HeN strain of mice; medium, RPMI 1640 tissue 
culture medium containing 0.1% C3H mouse serum. 
2 Pasternack, G.  R., R. J. Johnson, and H. S. Shin. Manuscript in preparation. 
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gauge needle.  After centrifugation  to  remove cells,  the ascites  fluid  was heated for  45 rain  at  56°C 
and again centrifuged at 40,000  g for 15 rain  to remove debris.  The tumor suppressive activity 
resided mainly in the IgG1 class  of  antibody.  3  To obtain nonimmune ascites,  mice were injected 
with saline-complete Freund's adjuvant without tumor cells.  It  was heated and cleared  in  the same 
way as the immune ascites  fluid. 
Experimental Tumor Inoculation.  In one calf  muscle, 0.05  ml of  a tumor cell  suspension or a 
mixture of  tumor and effector  cells  was injected.  Tumor growth was followed by caliper  measure- 
ment of  the calf  size  in  two diameters taken at  right  angles to  each other.  Values were recorded as 
the average of  the sum of  the two diameters for each measurement. 
Titration  of  Antibody.  All  immune or  nonimmune ascites  fluids  were administered to  the mice 
intraperitoneally within 1 h of  tumor inoculation unless otherwise mentioned. When suppressed 
by antibody, tumor growth was delayed. However, once tumor growth started  after  a delay, the 
slopes  of  the growth in individual mice were similar for control  and antibody-suppressed  groups. 
The delay of growth in individual mice was converted to percent suppression from the growth 
curve shown in Fig. 2. For example, if  antibody delayed the tumor growth, i.e.,  time required for 
leg diameter to  reach 8 ram, by 2.5  days, suppression was 90% (see  the Suppression as a Function 
of  Antibody Dose under Results).  If  tumor growth was suppressed over 22 days,  the suppression 
was considered to be 100% since  beyond this  point none of  the mice developed tumor for over 180 
day observation period.  In all experiments,  groups of  five  mice, caged separately,  were used as 
basic units.  The percent suppression of  the tumor in each of  five  mice was determined and the 
average and standard error  were calculated. Often duplicate groups were used. In such cases 
either  the average and standard error  from 10 mice from duplicate groups or the average of  the 
mean values from duplicate groups with a range of  means were presented. Each time a titration 
was performed, a control  experiment was done to  obtain a growth curve for  nonsuppressed tumor, 
like  the one shown in Fig. 2. 
Antibody Activity.  For a standard titration,  the amount of  antibody required to suppress the 
growth of  a 105  tumor cell  inoculum was measured, i  suppressive U was defined as the amount of 
antibody that could suppress the growth of  105  tumor cells  by 50%. The titer  of  the same antibody 
measured on different  days fluctuated due to unknown variables.  Therefore, when required, the 
amount of  antibody needed to  suppress the growth of 105  tumor cells  by 50% was determined as a 
control  for  each experiment. Two lots  of  immune ascites  fluid  were used. The lots  P-1 and P-2 each 
contained about 100 suppressive U of  antibody per milliliter  of  ascites  fluid. 
Effector Cells.  Lymphocytes  were isolated from peritoneal exudates induced by injecting 
intraperitoneally 3 ml of 2% starch hydrolysate  (Connaught  Medical Laboratories, Toronto, 
Canada) dissolved  in  0.15  M  NaCl. Starch was dissolved  by  boiling  the  suspension for  5  rain.  2  days 
after  injection  the mice were killed  by asphyxiation with CO2 and 5 ml of  medium were injected 
intraperitoneally. The mice were shaken gently,  the peritoneal  fluid  was aspirated,  and its cells 
were washed once in  the medium. Lymphocytes were purified  on a glass  bead column essentially 
as described by Shortman et  al. (13).  Such preparations contained more than 99% lymphocytes by 
morphology (5). 
To obtain macrophages, mice were given 3 ml each of  2.95% thioglycolate  (Difco  Laboratories, 
Detroit, Mich.) intraperitoneally. 5 days after  the injections,  the mice received 500 R whole-body 
irradiation to reduce the number of lymphocytes in the peritoneal exudate. 30-40 h later  the 
exudate was collected  by washing the peritoneum with 5 ml medium. The recovered cells  were 
washed twice in  medium and adjusted to  the desired  concentrations. Greater than 95% of  the  cells 
were macrophages. 
Vasoactive  Substances.  Bradykinin triacetate  was purchased from ICN, Nutritional Biochem- 
icals  Corp., Cleveland, Ohio and serotonin from Sigma Chemical Co.,  St. Louis, Mo. An intrader- 
real  injection  of  10 fig  of  bradykinin or 25 fig  of  serotonin,  each in 0.05  ml of  saline,  caused edema 
with average diameters of 7.2 mm  and 6.2 ram, respectively,  when measured 20 rain after  the 
injection. Saline controls  caused swelling with an average diameter of  5.3 ram. 
Autoradiography.  At various times after  tumor inoculation,  mice were given intraperitone- 
ally  0.25  ml of  saline  containing 25 ~Ci of  tritiated  thymidine (20 Ci/mM, New England Nuclear, 
3  Johnson, R. J., G. Pasternack, and H. S. Shin. Manuscript in preparation. 1276  TUMOR  SUPPRESSION  BY  ANTIBODY 
Boston, Mass.). The mice were killed 3, 6, and 16 h after pulse labeling and the calf muscles were 
fixed for  2 days in  a 10% formalin solution containing 1% calcium chloride. Tissue sections of  4 ~m 
thickness were processed for autoradiography as described (14).  Slides were dip-coated in Kodak 
NTB-2 emulsion. After a 20-day exposure they were developed in Kodak Dektol, fixed and stained 
with hematoxylin and eosin. Cells with more than five grains over the nuclear area were scored 
as positive.  200 tumor cells  were counted per mouse. 
Results 
The Growth Rate of the Tumor Cells.  Tumor cells ranging in numbers from 
103 to 106 were inoculated into the calf muscles of  mice and the increase in the leg 
diameters was followed. As shown in Fig.  1, the time period that the tumors 
remained macroscopically undetectable was inversely proportional to the size of 
the inoculum. Once the tumors became macroscopic, the slopes of the growth 
curves were the same for the different inocula. The plot of the time required for 
the leg diameter to reach 8 mm, the steepest portion of a growth curve, against 
the inoculum size on a semilogarithmic scale produced a straight line (Fig. 2). 
For each 10-fold difference in tumor cell number, a 2.5-day difference in reaching 
the 8-mm leg diameter was seen.  The generation time of 18 h  was calculated 
from the formula G =  0.3t/(loglo B-loglob) where G represents generation time, 
B the total cell number at the end of a given period of time, t, and b the initial 
cell number. 
The Lag Period for a Freshly Inoculated  Tumor.  When freshly inoculated 
into an animal, the tumor cells may stay dormant for a  period of time before 
they begin to divide. The straight line shown in Fig. 2 implies that the dormant 
or lag period and the generation time stay constant regardless of the inoculum 
size.  The  lag  period  was  determined  for  a  106  tumor  cell  inoculum.  Mice 
inoculated with 106 tumor cells were given tritiated thymidine at various times 
after tumor implantation. As shown in Fig. 3, the tumor cells began to incorpo- 
rate the label as early as 3 h after tumor implantation and the rate of the label 
incorporation  was  similar  among tumors  which  resided  in  the  animals for 
different periods of time. Therefore, the lag period was less than 3 h. A direct 
confirmation that an inoculum containing fewer cell numbers also had a  lag 
period of less than 3 h, as predicted by the growth curve, could not be carried out 
since when fewer cells were inoculated, significant numbers of tumor cells could 
not be detected in histological sections. 
Tumor Suppression as a Function of Antibody Dose.  The suppression of 105 
tumor cells by different doses of intraperitoneally administered antibody was 
measured.  In  normal  mice,  105  tumor  cells  caused  an  increase  in  the  leg 
diameter to  8  mm by  eight  days.  When  antibody was  administered,  tumor 
growth was delayed but the slopes of tumor growth in individual mice were the 
same once  growth  started in  a  group  suppressed  by antibody. The  delay in 
growth was converted to percent tumor suppression. For example, if the growth 
was delayed by 18 h, from the growth curve shown in Fig. 2, one could conclude 
that tumor was suppressed from 105 to an equivalent of 5  ×  104; this then was 
50%  suppression.  As shown in Fig.  4,  the dose response  curve seemed to be 
concave to the  abscissa.  Higher doses  of antibody caused more suppression. 
Nonimmune ascites at comparable amounts to immune ascites did not have any 
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FIG.  1.  Growth pattern of the tumor cells in normal C3H mice. Each point represents an 
average value  from  a  group  of five  mice.  Experiment  1,  e--e,  experiment  2,  A--A, 
experiment 3,  []--[], and experiment 4,  O--O,  were performed on different days. 
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Fro.  2.  Semi-logarithmic plot of the day the mean leg diameters reached 8 mm against the 
number of tumor cells in each inoculum. Data from Fig. 1. Symbols are the same as in Fig. 
1. 
Susceptibility of Tumor Cells that have Resided in an Animal as Compared to 
Freshly Injected  Tumor Cells.  It is possible that  tumor cells that have been 
growing for a  period of time in vivo are different from freshly injected tumor 
cells for various reasons. For example, fresh injection causes tissue damage and 
inflammation.  In addition,  freshly injected tumor cells are dispersed as single 
cells, but dividing tumor cells may form cell-nests which are not readily accessi- 
ble to antibody and  effectors.  In the  experiment presented  in Fig.  5,  3  ×  103 
tumor cells were inoculated and allowed to grow. On day 0, 1, 2, 3, 4, 5, 6, 7, 8, or 
9, 0.5 ml of immune ascites containing about 50 suppressive U of antibody were 
administered to test the susceptibility of the growing tumor. Again the delay in 
tumor growth was converted into percent suppression.  As shown in Fig. 5, the 
percentage  of tumor  cells  suppressed by antibody decreased as antibody was 1278  TUMOR  SUPPRESSION  BY  ANTIBODY 
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FIG.  3.  Mice inoculated with 106 tumor cells were pulsed with 25 tzCi of tritiated thymi- 
dine given intraperitoneally 3 h, 24 h, or 5 days after tumor implantation. Two mice from 
each group were killed at 3, 6, or 16 h after administration of the label. The calf muscles con- 
taining tumor cells were processed for autoradiography. Each point represents the mean 
value from two mice. The arrows indicate the time of tritiated thymidine injection. 
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Fro.  4.  Percent tumor suppression as a function of antibody dose. Each point represents 
mean value from 10 mice in two duplicate groups. The bars indicate the standard errors of 
the means. 
given later. The cause for the diminished suppression might lie in some of the 
possibilities  mentioned.  Alternatively, the  diminished suppression  could  be 
explained entirely on the basis of an increase in tumor cell number with passage 
of time, i.e., more antibody is needed to suppress a larger number of  tumor cells. 
On the basis of no lag period and an 18 h generation time, the number of tumor 
cells which must be present at any given time in an animal initially inoculated 
with 3  x  103  cells can be predicted.  The predicted numbers are indicated by 
arrows in the lower abscissa.  The suppression of freshly injected tumor cells, 
ranging in numbers from 3 x  103 to 107, was compared to that of growing tumor. 
As also shown in Fig. 5, the susceptibilities are virtually the same. The experi- SHIN,  ECONOMOU~  PASTERNACK,  JOHNSON~  AND  HAYDEN 
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Fro.  5.  Susceptibility of growing tumor,  0--0,  and freshly injected tumor,  C)--O,  ex- 
pressed as percent tumor cell suspension. The bottom abscissa shows the days the tumor 
grew before administration of 0.5 ml of  immune ascites containing about 50 suppressive U of 
antibody and the arrows indicate the predicted number of  tumor cells on the day of antibody 
administration, based on the 18-h  generation time and the absence of a  lag period. The 
assumption of a 3-h lag period does not significantly alter the graph. Each point represents 
the mean values of five mice. The bars indicate the standard errors of the means. 
ment  was  repeated twice with  similar results.  Therefore, in the  case  of this 
particular tumor,  and  within the range of tumor cell numbers and  antibody 
doses tested, there is no reason to believe that a growing or established tumor is 
different from a freshly injected tumor in its susceptibility to antibody-mediated 
suppression on a per cell basis. 
Tumor Size as a Factor Influencing the Effectiveness of Antibody in Tumor 
Suppression.  The amount of antibody needed to suppress 50%  of the tumor 
cells in inocula containing 105 or 10  e cells was compared. For the experiments, 
the immune ascites was administered 2 h before tumor inoculation to allow the 
antibody to equilibrate in the mice. One suppressive U  of antibody, by defini- 
tion, was needed to suppress 50% of 10  ~ tumor cells. If the amount of antibody 
needed to suppress 50% of the tumor cells is directly proportional to the number 
of tumor cells, in the same experiment one would expect the dose of antibody 
required to suppress 50% of 106 cells to be 10 suppressive U. In other words, the 
ratio of the number of tumor cells in an inoculum to the amount of antibody 
needed for 50% suppression would be constant regardless of  the number of  tumor 
cells present in the inoculum. Instead, as shown in Fig. 6,  30 suppressive U  of 
antibody were needed to achieve 50% suppression of l0  s cells. When tumor cells 
premixed with macrophages were tested, however, about 10 suppressive U were 
needed.  With the same method of titration as shown in Fig.  6,  in a  series of 
experiments we evaluated the effectiveness of antibody in suppressing 104, 3 × 
104, 105, or 106 tumor cells with or without premixed macrophages, lymphocytes, 
bradykinin, or serotonin. The results are shown in Fig. 7 in which effectiveness 
was expressed by the effectiveness index, defined as (number of tumor cells in 1280  TUMOR  SUPPRESSION  BY  ANTIBODY 
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FIG.  6.  The suppression of 108 tumor cells with or without exogenous macrophages. No 
added exogenous macrophages, 0--0,  exogenous macrophages to tumor cell ratio of hl, 
/x--/x, and 1:3, A--A. Each point represents the mean value of 10 mice. The bars indicate 
the standard errors of the means. 
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FIG.  7.  Effectiveness of antibody in suppressing varying numbers of tumor cells without 
exogenous vasoactive substances or effector cells (C), with 10 ~g of bradykinin (B), with 25 
~g of serotonin (S),  with exogenous macrophages equal in number to the tumor cells (M) 
and with exogenous lymphocytes twice the number of tumor cells (L).  Duplicate experi- 
ments were carried out  on  different days  and the average  values  are  given.  The  bars 
indicate the range of two values.  The ordinate shows tumor cell number as well as the 
antibody  effectiveness index defined as  (tumor  cell  number  in  the  inoculum)/(dose of 
antibody needed for 50% suppression in suppressive units ×  105). 
* No range of values is shown since the effectiveness of suppressing 105 tumor cells is 
always 1 x  10 -5 by definition. 
inoculum)/(dose of antibody needed for 50% suppression in suppressive units  × 
105).  Since 1 suppressive U  was defined as the amount of antibody needed to 
suppress 50% of a  l0  s tumor cell inoculum, the suppressive index for 105 tumor 
cell inoculum  is  always  1.  The  titer  of antibody measured  on different days 
fluctuated.  For  this  reason,  the  amount  of antibody  needed  to  cause  50% 
suppression of a  105 tumor cell inoculum was determined for each experiment as 
a  control. Then the amounts  of antibody required to suppress  50% of various 
other  tumor  cell  preparations  could  be  compared  to  this  control  value.  The 
effectiveness indices were approximately 1 for 104 and 3  ×  104 tumor cells but 
dropped to 0.3 for l0  s tumor cells. The effectiveness index was restored to about 1 SHIN,  ECONOMOU,  PASTERNACK,  JOHNSON,  AND  HAYDEN  1281 
when 10  6 tumor cells premixed with macrophages were tested. Bradykinin and 
serotonin did not affect the effectiveness of antibody in suppressing  10  5 or 10  6 
tumor cells.  Lymphocytes, unlike macrophages,  did not improve the effective- 
ness in the suppression of 10  6 tumor cells. Exogenous macrophages added to 10  5 
tumor cells diminished  the effectiveness index to the level of 0.7.  The results 
indicate that at the 10  5 tumor cell level, the suppression by antibody takes place 
in  an  optimal  manner  in  the  sense  that  added  macrophages  or  vasoactive 
substances  do  not  improve  the  effectiveness of antibody.  If anything,  added 
macrophages decreased the effectiveness. However, at the 10  6 tumor cell level 
effectiveness diminishes  due to the development of a  macrophage  shortage;  a 
shortage  of lymphocytes was  not  detected.  Injection  of agents  that  increase 
vascular permeability did not restore the effectiveness. It is important to point 
out that the growth rates of tumor cells premixed with macrophages,  lympho- 
cytes, bradykinin, or serotonin were the same as the growth rates of a compara- 
ble number of tumor cells alone indicating that under the experimental condi- 
tions  mentioned  these  effector  cells  and  vasoactive  substances  do  not  have 
suppressive activity without antibody. 
Discussion 
In  our  study  we  evaluated  some  of the  factors  which  might  potentially 
influence  the  effectiveness of antibody in  mediating  tumor  suppression.  The 
effect of the time of tumor residency in vivo was examined first for the following 
reasons.  Under the  usual  experimental  conditions,  the tumor cells were har- 
vested from donors, dispersed into single cell suspensions, counted and injected 
into recipients.  Injection causes trauma.  When tested for their susceptibility to 
antibody,  such cells existing as single cells in an inflamed area may respond 
differently than  a  more "natural"  tumor  that  has  grown  in  an  animal  for a 
period of time without a  significant traumatic inflammatory reaction and has 
formed nests of cells from the initially isolated single cells. Experimental results 
indicate that whatever difference there may be between growing tumor cells and 
a  comparable number of freshly injected tumor cells, that difference per se did 
not alter the effectiveness of antibody in causing tumor suppression within the 
range of the tumor cell numbers and antibody doses tested. On the other hand, 
when the tumor size became large, the effectiveness of antibody diminished due 
to the development of a macrophage shortage. Substances that increase vascular 
permeability or exogenous lymphocytes did not correct this diminished antibody 
effectiveness, indicating that diffusion of antibody or a shortage of lymphocytes 
were  not problems.  The  ineffectiveness of lymphocytes might  be due to two 
reasons.  Either  a  lymphocyte shortage  truly  was  not  a  problem,  or alterna- 
tively, the immune ascites used in this experiment did not contain the appropri- 
ate  class  of antibody to cooperate with lymphocytes.  Johnson  and  Shin  have 
shown that mouse IgG1 caused tumor suppression in cooperation with macro- 
phages  but  not  with  lymphocytes  (9).  Preliminary  studies  indicate  that  the 
tumor suppressive activity of the immune  ascites resides mainly in the IgG1 
class of antibody  3 making the latter possibility a likely one. Classes of antibody 
that can suppress tumor in cooperation with lymphocytes are needed to deter- 
mine whether a  shortage of lymphocytes may also develop at high tumor cell 
numbers. In any case, one of the major obstacles in suppressing a large number 1282  TUMOR  SUPPRESSION  BY  ANTIBODY 
of tumor cells is the development of a  macrophage  shortage.  It is not known 
whether this problem is due to a  factor(s) from the tumor that interferes with 
macrophage  functions  (15-17).  The  loss of effectiveness of antibody in tumor 
suppression  due  to  the  development  of  an  effector  shortage  suggests  that, 
depending on the situation,  the suppressive activity or enhancing activity of a 
class of antibody may prevail. Thus, the IgG1, IgG2, and IgM classes of antibody 
were shown to have both suppressive and enhancing activities (8, 9,  18, 19). At 
low  tumor  cell  numbers,  the  suppressive  activity  of such  antibody  will  be 
sufficient to cause tumor suppression even after the expression and (or) develop- 
ment  of the  host's  active  immunity  has  been blocked.  Therefore,  enhancing 
activity of antibody may be masked. However, at large cell numbers, due to the 
development of effector shortage,  suppressive activity of antibody will sharply 
diminish.  Under such conditions only the enhancing  or blocking activity will 
manifest itself. 
At the 105 tumor cell level, suppression takes place in an optimal manner in 
the  sense  that  added  effector cells  or  the  substances  that  increase  vascular 
permeability  did  not  make  the  suppression  any  more  effective.  In  addition, 
below the  105 tumor cell level,  the amount of antibody needed to achieve the 
same fraction  of tumor suppression  is directly proportional  to the number  of 
tumor cells in the inoculum, unlike many tumorcidal agents which operate in a 
"first-order fashion" and therefore require a  constant dose to eliminate  a  con- 
stant fraction, regardless of tumor cell number (20). Furthermore,  it takes only 
a few micrograms of antibody to cause a prolonged, if not permanent,  suppres- 
sion of 10  ~ tumor cells. 3 Suppression can occur even in the absence of a  host's 
active immune responses (5). These attributes of antibody-mediated suppression 
make immunotherapy of a small number of tumor cells by passive antibody an 
attractive possibility. 
Summary 
In the suppression of the growth of a mouse lymphoma 6C3HED by antibody, 
the effectiveness of antibody in suppressing growing or established tumor cells 
and comparable number of freshly injected tumor cells is quantitatively similar. 
The effectiveness of antibody diminishes markedly when the number of tumor 
cells per mouse reaches the level of 10  e due to the development of a macrophage 
shortage. At the 105 tumor cell level, antibody-mediated suppression takes place 
in an optimal manner and between 105 and 104 tumor cell numbers, the amount 
of antibody required to suppress 50% of the tumor cells is directly proportional to 
the number of tumor cells suppressed. 
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